Literature DB >> 25998294

Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia.

Pratik Choudhary1, Michael R Rickels2, Peter A Senior3, Marie-Christine Vantyghem4, Paola Maffi5, Thomas W Kay6, Bart Keymeulen7, Nobuya Inagaki8, Frantisek Saudek9, Roger Lehmann10, Bernhard J Hering11.   

Abstract

Problematic hypoglycemia, defined as two or more episodes per year of severe hypoglycemia or as one episode associated with impaired awareness of hypoglycemia, extreme glycemic lability, or major fear and maladaptive behavior, is a challenge, especially for patients with long-standing type 1 diabetes. Individualized therapy for such patients should include a composite target: optimal glucose control without problematic hypoglycemia. Therefore, we propose a tiered, four-stage algorithm based on evidence of efficacy given the limitations of educational, technological, and transplant interventions. All patients with problematic hypoglycemia should undergo structured or hypoglycemia-specific education programs (stage 1). Glycemic and hypoglycemia treatment targets should be individualized and reassessed every 3-6 months. If targets are not met, one diabetes technology-continuous subcutaneous insulin infusion or continuous glucose monitoring-should be added (stage 2). For patients with continued problematic hypoglycemia despite education (stage 1) and one diabetes technology (stage 2), sensor-augmented insulin pumps preferably with an automated low-glucose suspend feature and/or very frequent contact with a specialized hypoglycemia service can reduce hypoglycemia (stage 3). For patients whose problematic hypoglycemia persists, islet or pancreas transplant should be considered (stage 4). This algorithm provides an evidence-informed approach to resolving problematic hypoglycemia; it should be used as a guide, with individual patient circumstances directing suitability and acceptability to ensure the prudent use of technology and scarce transplant resources. Standardized reporting of hypoglycemia outcomes and inclusion of patients with problematic hypoglycemia in studies of new interventions may help to guide future therapeutic strategies.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25998294      PMCID: PMC4439532          DOI: 10.2337/dc15-0090

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  109 in total

1.  Response to nocturnal alarms using a real-time glucose sensor.

Authors:  Bruce Buckingham; Jen Block; Jonathan Burdick; Andrea Kalajian; Craig Kollman; Michael Choy; Darrell M Wilson; Peter Chase
Journal:  Diabetes Technol Ther       Date:  2005-06       Impact factor: 6.118

2.  Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway.

Authors:  T Skrivarhaug; H-J Bangstad; L C Stene; L Sandvik; K F Hanssen; G Joner
Journal:  Diabetologia       Date:  2005-12-20       Impact factor: 10.122

3.  Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality.

Authors:  Trevor J Orchard; David M Nathan; Bernard Zinman; Patricia Cleary; David Brillon; Jye-Yu C Backlund; John M Lachin
Journal:  JAMA       Date:  2015-01-06       Impact factor: 56.272

4.  Frequency of biochemical hypoglycaemia in adults with Type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring.

Authors:  P Choudhary; J Geddes; J V Freeman; C J Emery; S R Heller; B M Frier
Journal:  Diabet Med       Date:  2010-06       Impact factor: 4.359

5.  Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group.

Authors: 
Journal:  Diabetes       Date:  1997-02       Impact factor: 9.461

6.  Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes.

Authors:  J Geddes; J E Schopman; N N Zammitt; B M Frier
Journal:  Diabet Med       Date:  2008-04       Impact factor: 4.359

7.  Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults.

Authors:  Richard G Feltbower; H Jonathan Bodansky; Christopher C Patterson; Roger C Parslow; Carolyn R Stephenson; Catherine Reynolds; Patricia A McKinney
Journal:  Diabetes Care       Date:  2008-02-19       Impact factor: 19.112

Review 8.  The current state of pancreas transplantation.

Authors:  Rainer W G Gruessner; Angelika C Gruessner
Journal:  Nat Rev Endocrinol       Date:  2013-07-30       Impact factor: 43.330

9.  A psychoeducational program to restore hypoglycemia awareness: the DAFNE-HART pilot study.

Authors:  Nicole de Zoysa; Helen Rogers; Marietta Stadler; Carla Gianfrancesco; Susan Beveridge; Emma Britneff; Pratik Choudhary; Jackie Elliott; Simon Heller; Stephanie A Amiel
Journal:  Diabetes Care       Date:  2013-12-06       Impact factor: 19.112

10.  Restoration of Glucose Counterregulation by Islet Transplantation in Long-standing Type 1 Diabetes.

Authors:  Michael R Rickels; Carissa Fuller; Cornelia Dalton-Bakes; Eileen Markmann; Maral Palanjian; Kevin Cullison; Janice Tiao; Shiv Kapoor; Chengyang Liu; Ali Naji; Karen L Teff
Journal:  Diabetes       Date:  2014-12-18       Impact factor: 9.461

View more
  47 in total

1.  Transplantation: Sustained benefits of islet transplants for T1DM.

Authors:  Bernhard J Hering; Melena D Bellin
Journal:  Nat Rev Endocrinol       Date:  2015-08-04       Impact factor: 43.330

2.  Benefits of Islet Transplantation as an Alternative to Pancreas Transplantation: Retrospective Study of More Than 10 Ten Years of Experience in a Single Center.

Authors:  Barbora Voglová; Martina Zahradnická; Peter Girman; Jan Kríž; Zuzana Berková; Tomáš Koblas; Ema Vávrová; Lenka Németová; Lucie Kosinová; David Habart; Eva Fábryová; Eva Dovolilová; Ivan Leontovyc; Tomáš Neškudla; Jan Peregrin; Jozef Kovác; Kvetoslav Lipár; Matej Kocík; Tomáš Marada; Jirí Svoboda; František Saudek
Journal:  Rev Diabet Stud       Date:  2017-06-12

Review 3.  Type 1 diabetes: where are we in 2017?

Authors:  Melanie Copenhaver; Robert P Hoffman
Journal:  Transl Pediatr       Date:  2017-10

4.  The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC).

Authors:  William H Herman; Barbara H Braffett; Shihchen Kuo; Joyce M Lee; Michael Brandle; Alan M Jacobson; Lisa A Prosser; John M Lachin
Journal:  J Diabetes Complications       Date:  2018-06-12       Impact factor: 2.852

Review 5.  Advances in β-cell replacement therapy for the treatment of type 1 diabetes.

Authors:  Marie-Christine Vantyghem; Eelco J P de Koning; François Pattou; Michael R Rickels
Journal:  Lancet       Date:  2019-09-15       Impact factor: 79.321

Review 6.  Defining Outcomes for β-cell Replacement Therapy in the Treatment of Diabetes: A Consensus Report on the Igls Criteria From the IPITA/EPITA Opinion Leaders Workshop.

Authors:  Michael R Rickels; Peter G Stock; Eelco J P de Koning; Lorenzo Piemonti; Johann Pratschke; Rodolfo Alejandro; Melena D Bellin; Thierry Berney; Pratik Choudhary; Paul R Johnson; Raja Kandaswamy; Thomas W H Kay; Bart Keymeulen; Yogish C Kudva; Esther Latres; Robert M Langer; Roger Lehmann; Barbara Ludwig; James F Markmann; Marjana Marinac; Jon S Odorico; François Pattou; Peter A Senior; James A M Shaw; Marie-Christine Vantyghem; Steven White
Journal:  Transplantation       Date:  2018-09       Impact factor: 4.939

7.  Islet-after-failed-pancreas and pancreas-after-failed islet transplantation: Two complementary rescue strategies to control diabetes.

Authors:  Axel Andres; Scott Livingstone; Tatsuya Kin; Patricia M Campbell; Peter A Senior; Norman M Kneteman; David Bigam; A M James Shapiro
Journal:  Islets       Date:  2015       Impact factor: 2.694

8.  Long-Term Improvement in Glucose Control and Counterregulation by Islet Transplantation for Type 1 Diabetes.

Authors:  Michael R Rickels; Amy J Peleckis; Eileen Markmann; Cornelia Dalton-Bakes; Stephanie M Kong; Karen L Teff; Ali Naji
Journal:  J Clin Endocrinol Metab       Date:  2016-08-29       Impact factor: 5.958

9.  Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia.

Authors:  Bernhard J Hering; William R Clarke; Nancy D Bridges; Thomas L Eggerman; Rodolfo Alejandro; Melena D Bellin; Kathryn Chaloner; Christine W Czarniecki; Julia S Goldstein; Lawrence G Hunsicker; Dixon B Kaufman; Olle Korsgren; Christian P Larsen; Xunrong Luo; James F Markmann; Ali Naji; Jose Oberholzer; Andrew M Posselt; Michael R Rickels; Camillo Ricordi; Mark A Robien; Peter A Senior; A M James Shapiro; Peter G Stock; Nicole A Turgeon
Journal:  Diabetes Care       Date:  2016-04-18       Impact factor: 19.112

Review 10.  Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop.

Authors:  Michael R Rickels; Peter G Stock; Eelco J P de Koning; Lorenzo Piemonti; Johann Pratschke; Rodolfo Alejandro; Melena D Bellin; Thierry Berney; Pratik Choudhary; Paul R Johnson; Raja Kandaswamy; Thomas W H Kay; Bart Keymeulen; Yogish C Kudva; Esther Latres; Robert M Langer; Roger Lehmann; Barbara Ludwig; James F Markmann; Marjana Marinac; Jon S Odorico; François Pattou; Peter A Senior; James A M Shaw; Marie-Christine Vantyghem; Steven White
Journal:  Transpl Int       Date:  2018-04       Impact factor: 3.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.